Navigation Links
Health of Patients with Nonalcoholic Steatohepatitis Improved Through Treatment with Anti-CD3 Antibodies
Date:11/7/2011

SAN FRANCISCO, Nov. 7, 2011  /PRNewswire/ -- Nonalcoholic steatohepatitis (NASH) is a major cause of cirrhosis and is growing in incidence in the United States. By treating patients with NASH with orally administered anti-CD3 monoclonal antibodies, researchers at Hadassah Medical Center and NasVax Ltd in Israel were able to improve clinical biomarkers for insulin resistance as well as liver enzyme levels.

The presentation of the study at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (Monday, November 7), is on the results of a phase IIa blinded, placebo-controlled trial. Previous studies in animal models showed improvement in inflammation and autoimmunity. The purpose of this clinical trial was to determine safety and trends in clinical biomarkers and immune-modulation in patients with NASH.

The 36 subjects received one of three dosage levels of oral antibody immunotherapy or placebo once daily for 30 days, followed by an additional 30 days of observation. In addition to assessing a broad range of safety parameters, patients were tested for liver enzymes, glucose, lipid profile, oral glucose tolerance, serum cytokines, and regulatory T cells. Treatment was safe and very well tolerated, and no treatment-related adverse events were noted for any of the patients.

Because of the positive results of the study, lead researcher Dr. Mizrahi, said, "We think that these data are promising for the treatment of inflammatory diseases. The mechanism of action, which is the induction of regulatory T cells for the suppression of inflammation, is distinct from other therapies that have been investigated to date. Consequently we have intensified our effort to progress further clinical development in NASH and complete the ongoing Phase IIa trial in Hepatitis C."

Abstract title:

Oral administration of anti-C03 MAb to patients with NASH is safe, promotes regulatory T cells, decreases liver enzymes, and alleviates insulin resistance: Results of a phase IIA blinded placebo-controlled trial

Oral administration of anti-C03 MAb to patients with NASH is safe, promotes regulatory T cells, decreases liver enzymes, and alleviates insulin resistance: Results of a phase IIA blinded placebo-controlled trial

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in San Francisco, California, November 4 – 8, will bring together more than 8,000 researchers from 55 countries.

A press room will be available from November 5 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org.

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Tone Deafness Explained, from the Harvard Health Letter
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
8. ViroPharma to Present at Three Upcoming Healthcare Conferences
9. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
10. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/9/2017)... ... ... Monday, September 18 th .The Brain Tumor Foundation (BTF) begins a week-long ... BTF,s Mobile MRI Unit – a 70 Ft. ... brings its nationwide initiative, the Road to Early Detection Sponsor-A-City Campaign to ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
Breaking Medicine News(10 mins):